Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Takes The Measure Of Bulk Caffeine In Warnings About Labels

This article was originally published in The Tan Sheet

Executive Summary

Serving amounts such as one-sixteenth of a teaspoon indicated on product labels “cannot be accurately measured using common household measuring tools,” FDA says. NPA, however, suggests the agency gives too little credit to consumers’ measuring skills.

You may also be interested in...



Novelty Store's Bulk Caffeine Unamusing To US FDA

CFSAN warning letter says Trippo Internationals 16-ounce caffeine product “is packaged to contain an amount that is potentially lethal many times over” and the “packaging requires the consumer to use a precise scale to separate out a safe serving from this potentially lethal amount.”

FDA Guidance Stirs In Caffeine Restrictions For Supplements

"An inherent feature of the conditions of use for such products is that the consumer must separate out a very small, precise serving from a potentially lethal amount of product – a task that poses a significant or unreasonable risk of illness or injury," says FDA's Office of Dietary Supplement Programs. Only products containing pure caffeine that packaged in the ingredient in premeasured doses and bulk caffeine that is sufficiently diluted will be considered compliant.

Undisclosed Allergen, Caffeine Claims Prompt Supplement Recalls

Firms marketing supplements found to contain steroid ingredients also are recalling products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel